Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 1,516 Cr.
- Current Price ₹ 917
- High / Low ₹ 999 / 300
- Stock P/E 46.5
- Book Value ₹ 170
- Dividend Yield 0.03 %
- ROCE 21.3 %
- ROE 15.6 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 97.8 to 53.2 days.
Cons
- Promoter holding has decreased over last 3 years: -5.05%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 454 | 635 | |
| 401 | 545 | |
| Operating Profit | 52 | 91 |
| OPM % | 12% | 14% |
| 2 | 4 | |
| Interest | 22 | 39 |
| Depreciation | 5 | 8 |
| Profit before tax | 27 | 47 |
| Tax % | 28% | 31% |
| 20 | 33 | |
| EPS in Rs | 13.90 | 19.89 |
| Dividend Payout % | 2% | 1% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 60% |
| 5 Years: | 46% |
| 3 Years: | 52% |
| 1 Year: | 190% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 5 | 5 |
| Reserves | 137 | 273 |
| 167 | 222 | |
| 179 | 142 | |
| Total Liabilities | 487 | 642 |
| 53 | 118 | |
| CWIP | 0 | 0 |
| Investments | 2 | 2 |
| 433 | 522 | |
| Total Assets | 487 | 642 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -17 | 12 | |
| -6 | -74 | |
| 27 | 121 | |
| Net Cash Flow | 4 | 60 |
| Free Cash Flow | -23 | -62 |
| CFO/OP | -32% | 13% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 142 | 53 |
| Inventory Days | 267 | 219 |
| Days Payable | 161 | 71 |
| Cash Conversion Cycle | 248 | 201 |
| Working Capital Days | 76 | 78 |
| ROCE % | 21% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Capsules Capacity millions per day ・Standalone data |
|
||||||||
| Granulation Capacity kgs per day ・Standalone data |
|||||||||
| Tablet Compression Capacity millions per day ・Standalone data |
|||||||||
| Countries with Product Registration / Export Presence countries ・Standalone data |
|||||||||
| Cumulative Registered Products (Final Registrations) products ・Standalone data |
|||||||||
| Products Under Registration (Pipeline) products ・Standalone data |
|||||||||
| Contract / Third-Party Manufacturing Locations locations ・Standalone data |
|||||||||
| Total SKUs (Stock Keeping Units) SKUs ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment
17 Jul - Fredun Pharmaceuticals allotted 1,10,25,380 bonus shares in 2:1 ratio on July 17, 2026.
- Intimation Of Record Date Pursuant To Regulation 42 Of The SEBI (LODR) Regulations, 2015 For Issue Of Bonus Equity Shares. 10 Jul
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Jul - Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Jun - 39th AGM on June 30, 2026 approved 11 resolutions, including 7% dividend, bonus shares, capital and borrowing increases.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Jun - 39th AGM approved 7% dividend, bonus issue, capital increase, borrowing limits and related-party transactions.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
Jun 2026TranscriptPPTREC
-
Feb 2026TranscriptPPT
-
Nov 2025TranscriptPPTREC
-
Aug 2025TranscriptPPTREC
-
Jun 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
Business Overview:{# https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ad9e590-baf1-43e5-a921-d0d5a2e4d356.pdf#page=2#}
The company is a diversified healthcare company engaged in pharmaceuticals, nutraceuticals, cosmeceuticals, dietary supplements, and animal healthcare products. Its pharmaceutical portfolio spans multiple therapeutic areas, including antihypertensives, antidiabetics, antiretrovirals (ARVs), and narcotics.